Why it Works: Multi-dimensional formula addresses the facial changes that occur when using GLP-1 agonists Formula works in 4D to improve the appearance of facial skin deflation, loose, sagging, crepey skin texture, dehydration, and deep wrinkles Proprietary XOSM technology boosts formula performance Improves the appearance of skin firmness, density and skin texture quality Deeply nourishes and hydrates, plumping the skin Protects and nourishes the skins barrier Clinicals: 20.1% increase in facial volume 22.5% increase in firmness 23.2% increase in net elasticity 20.7% decrease in wrinkles 21.8% increase in hydration Disclaimer: Based on a 12-week clinical study of 29 participants ages 3565, who have experienced weight loss due to the use of one of the following: GLP-1 agonists, GIP, other weight loss promoting drugs or gastric bypass surgery, with twice daily application of VOL.U.LIFT
In addition, intermittent dosing may be less likely to make the person living with obesity feel medicalized by removing the ritual of daily medication
The short-term risks from dehydration and constipation are manageable with the prevention strategies outlined in this guide
FOXO4-DRI is not approved for human use by the FDA or any regulatory agency
Alison Kraayvanger of the Neighbourhood Pharmacy Association of Canada said pharmacists are able to substitute the generic for the brand product in accordance with existing provincial substitution rules, unless the prescriber has indicated otherwise or there is a clinical reason the patient requires the brand product [Source: globalnews.ca/news/11857122/generic-semaglutide-canada-sales-begin]
